AC Immune SA

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.




https://finviz.com/published_idea.ashx?t...081117900i

AC Immune
Biontech-Investoren steigen beim Alzheimer-Spezialisten ein
von Jürgen Salz
07. November 2021
Prominenter Einstieg bei AC Immune: Das Investorenduo Andreas und Thomas Strüngmann, das auch an Biontech beteiligt ist, investiert in größerem Stil. Das Schweizer Unternehmen will Medikamente gegen Alzheimer entwickeln.
https://www.wiwo.de/unternehmen/industri...72700.html


AC Immune says number of families affected by Alzheimer's could nearly triple by 2050
Sun, November 7, 2021, 1:53 PM
FRANKFURT, Nov 7 (Reuters) - Alzheimer's drug developer AC Immune expects the number of families to be affected by the degenerative disease could nearly triple by 2050 to 150 million, its CEO said in an interview with a German magazine.
https://finance.yahoo.com/news/ac-immune...30315.html